Alliances
BGE-105 (formerly AMG 986) mimics the production of apelin, a peptide that has been found in animal studies to improve muscle regeneration and decrease mouse frailty.
Under the terms of the deal, SciNeuro is paying Lilly cash upfront as well as various milestone payments and royalties. No financial details were disclosed.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
Recently announced topline results from a Phase II study show SAGE-324, Sage Therapeutics’ investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, significantly reduced tremor score in adult patients with essential tremor.
Clinical-stage biotech company Celcuity announced Thursday that it had entered into a global licensing agreement with Pfizer to develop and commercialize gedatolisib, the latter company’s first-in-class PI3K/mTOR inhibitor for the treatment of breast cancer.
Artios Pharma Limited has entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DDR targets and enhancing Novartis’ radioligand therapies.
The New York-based company inked a deal with Microsoft to develop unique digital pathology tools for oncology and also announced its seed funding round was extended from $12 million to $44 million.
Valence Discovery just announced a strategic alliance with Charles River Laboratories to make its artificial intelligence (AI) and machine learning (ML) platform available to Charles River’s clients.
Cidara Therapeutics inked a deal worth up to $780 million with Johnson & Johnson to develop and commercialize Cidara’s candidate CD388 for the prevention and treatment of seasonal and pandemic influenza.
QED Therapeutics, an affiliate of BridgeBio Pharma, announced today their global collaboration and licensing agreement with Helsinn Group.
PRESS RELEASES